Quantcast

Latest Fixed dose combination Stories

2011-07-18 04:30:00

MONTGOMERY, Ala. and INDIANAPOLIS, July 18, 2011 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) today released new study results that investigated the potential interaction of cholesterol drug LIVALO (pitavastatin) 4 mg in healthy volunteers taking the protease inhibitor (PI) combination lopinavir/ritonavir, a fixed dose combination drug for the treatment of HIV infection.(1) Protease inhibitors are commonly used antiretroviral HIV medications.(2)...

2011-07-15 12:47:00

CHAPEL HILL, N.C., July 15, 2011 /PRNewswire/ -- The pharmaceutical industry is under constant pressure to produce new products and fixed dose combination therapies are one of the industry's strategies to offset lackluster pipelines and patent loss. But there is more to success than just developing a new FDC and launching it - successful research and development leaders recognize that understanding the market and audience will smooth the FDC launch process, according to a Best Practices,...

2011-07-06 00:10:16

Infants of human immunodeficiency virus 1 (HIV-1) infected mothers who were treated before and after birth with the protease inhibitor lopinavir-ritonavir were more likely to experience adrenal dysfunction, including life-threatening adrenal insufficiency in premature infants, compared with a zidovudine-based regimen, according to a preliminary report in the July 6 issue of JAMA. "The HIV-l transmission rate to newborns is now less than 1 percent for women treated during pregnancy. For...

2011-05-23 09:00:00

DEERFIELD, Ill., May 23, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc. U.S., (TGRD U.S.) today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD). In two phase 3 studies, azilsartan medoxomil combined in a fixed-dose with CLD lowered clinic systolic blood pressure (SBP) significantly more than the fixed-dose combination of olmesartan medoxomil plus hydrochlorothiazide...

9dd9ef066dd9141be31d69f8f24ae0571
2011-04-18 13:56:36

Researchers are stopping tests of a daily pill to prevent infection with the AIDS virus in thousands of African women. The study was stopped because partial results show no signs that the drug is preventing the virus. The study found that women taking Truvada, made by Gilead Sciences Inc., are just as likely to get HIV as other women who have been given dummy pills.  Researchers said that even if the study were to continue it would not be able to determine whether the pills help prevent...

2011-04-13 07:43:06

(Ivanhoe Newswire) -- In patients with newly-diagnosed tuberculosis (TB), use of a combined four-drug, fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a new study. "Despite the availability of a highly effective 6-month chemotherapy regimen, worldwide control of tuberculosis is severely impeded by poor treatment completion rates that threaten the emergence of multidrug resistance," according to background information in the article....

2011-04-12 14:15:21

In patients with newly diagnosed tuberculosis (TB), use of a combined 4-drug fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a study in the April 13 issue of JAMA, a theme issue on infectious disease and immunology. Christian Lienhardt, M.D., M.Sc., Ph.D., of the World Health Organization, Geneva, Switzerland, presented the findings of the study at a JAMA media briefing at the National Press Club. Dr. Lienhardt conducted the study while...

2011-03-24 15:05:00

CHAPEL HILL, N.C., March 24, 2011 /PRNewswire/ -- The pharmaceutical industry has turned to lifecycle planning as one of the strategies to offset lackluster pipelines and patent loss. Fixed dose combination (FDC) products not only offer an opportunity to extend patent life for branded products but also the chance to offer payers and patients a differentiated product with a therapeutic benefit. Unfortunately, getting to market quickly with an FDC is more myth than reality. On average, it...

2011-02-03 02:00:00

LONDON, Feb. 3, 2011 /PRNewswire/ -- Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV. The new investigational regimen, known as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 ('572) and ViiV Healthcare's combination nucleoside reverse transcriptase inhibitor (NRTI)...

2011-01-20 06:00:00

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg. The NDA is based on the reference listed drug Combivir®, by ViiV Healthcare. This innovative pediatric fixed-dose...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related